Asunto(s)
Anticonvulsivantes/efectos adversos , Muerte Súbita Cardíaca/etiología , Epilepsia/tratamiento farmacológico , Epilepsia/fisiopatología , Triazinas/efectos adversos , Acidosis/complicaciones , Acidosis/etiología , Acidosis/fisiopatología , Factores de Edad , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/sangre , Apnea/complicaciones , Apnea/fisiopatología , Arritmias Cardíacas/inducido químicamente , Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/fisiopatología , Muerte Súbita Cardíaca/prevención & control , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Femenino , Humanos , Lamotrigina , Factores de Riesgo , Factores Sexuales , Triazinas/administración & dosificación , Triazinas/sangreRESUMEN
OBJECTIVES: Lamotrigine (LTG) has recently been shown to inhibit the cardiac rapid delayed rectifier potassium ion current (Ikr). Ikr-blocking drugs may increase the risk of cardiac arrhythmia and sudden unexpected death. With this background, it may be of importance that in our outpatient clinic between August 1, 1995 and August 1, 2005 we registered four consecutive cases of sudden unexpected death in epilepsy (SUDEP) in non-hospitalized patients that were all being treated with LTG in monotherapy. Here we describe and discuss these cases, the relevant literature, and the reasons to question whether these events were as a result of coincidence alone. METHODS: All the cases were collected consecutively at the outpatient clinic, Department of Neurology, Stavanger University Hospital, Norway. Clinical and pathological data were obtained and the relevant literature reviewed. RESULTS: All were females with idiopathic epilepsy. CONCLUSIONS: A systematic study is needed to reveal whether LTG may increase the risk of SUDEP in certain groups of patients.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Muerte Súbita Cardíaca/etiología , Epilepsia/tratamiento farmacológico , Triazinas/uso terapéutico , Adolescente , Adulto , Anticonvulsivantes/efectos adversos , Epilepsia/complicaciones , Epilepsia/mortalidad , Femenino , Humanos , Lamotrigina , Triazinas/efectos adversosRESUMEN
OBJECTIVES: The postpolio syndrome (PPS) is said to comprise symptoms which are characteristic of a specific disorder affecting former polio sufferers many years after their acute disease. Localized muscular weakening with or without attendant pain and atrophy are claimed to separate patients with PPS from persons with unspecific common symptoms from the musculoskeletal system. Therefore our objective was to evaluate the specificity of the symptoms of the PPS. MATERIAL AND METHODS: Eighty-one former polio sufferers were, based on clinical examination and a questionnaire, compared with 116 gender and age matched controls. RESULTS: Significant differences between patients and controls of self-reported muscular weakening and pain in different locations were found. However, the level of similar complaints reported by the controls also was considerable. CONCLUSION: We question the validity of the diagnosis in cases without localized atrophy or other objective signs of denervation.
